Category: CBDiary

Cannabis use Promotes Physical Fitness!

By Fred Gardner Another newsworthy study that didn’t make the news has been brought to our attention: The Effect of Medical Marijuana Laws on Body Weight by San Diego State policy analyst Joseph J. Sabia and colleagues. Now that more than 20 states have enacted medical marijuana laws (MMLs), “big data” can be compiled and correlations made between marijuana use and impacts on the population. It turns out that access to the herb leads to a measurably leaner citizenry! Sabia et al attribute the result to two mechanisms: young adults using marijuana as a substitute for alcohol, and those over 35 getting pain relief enabling them to exercise more. ...

Read More

Cannabis as a treatment for autism

The Israeli filmmaker Zach Klein is following up his Raphael Mechoulam biopic The Scientist with a documentary about cannabis as a treatment for autism. I received this note from Klein, along with an image from his new project: I’m editing my documentary about autism (and cannabis) and I think that Mechoulam is looking at O’Shaughnessy’s. Picture is attached. Did you publish something about the subject? The page from O’Shaughnessy’s  that Mechoulam was looking was from our Summer 2009 issue. It contained two brief case reports by Philip Denney, MD.  A colleague of Mechoulam’s had evidently put the page in an envelope and mailed it...

Read More

Senate Drug Caucus Holds Hearing on CBD

By Fred Gardner The Senate Caucus on International Narcotics Control was created in 1985 (the height of the Ronald Reagan era) and given special powers to issue subpoenas and call hearings. Chairman Chuck Grassley (Republican, Iowa), arranged for a hearing June 24, 2015 on “Barriers to Cannabidiol Research and Potential Medical Benefits.” After opening statements by Grassley and his Democratic counterpart, Dianne Feinstein of California, three Senators who have introduced CBD-related bills —Orrin Hatch, Kirsten Gillibrand, and Cory Booker laid out their views. Then came testimony by Joe Rannazzasi of the DEA, Dr. Douglas Throckmorton a deputy director at FDA,...

Read More

Will FDA nix CBD in ‘Natural Products?’

February 15 from O’S News Service An SCC member forwarded this item on Friday with the comment/question: “Thanks, GW?”  The article is by Todd Runestad and ran in newhope360, a site that covers the “Natural Products” industry. Here’s the kernel: … once a drug has been recognized by the FDA, it can never become a supplement. And it turns out that GW Pharmaceuticals, based in the U.K., gained Investigational New Drug (IND) status and conducted a clinical trial on a CBD product in 2007, which allows a fast track for compounds for rare diseases where patients do not respond to any other conventional medicines....

Read More

How CBD Regulates Gene Expression

By Adrian Devitt-Lee and Martin A Lee There is growing interest among medical scientists in the gene-regulating properties of cannabidiol (CBD), the non-psychoactive plant cannabinoid. Researchers at the California Pacific Medical Center have shown that CBD reduces brain cancer and breast cancer cell proliferation and metastasis by inhibiting the expression of the ID-1 gene. ID-1 expression is implicated in several kinds of aggressive cancer. In 2012, Israeli scientists identified more than 1,200 genes affected by CBD. Some 680 “gene transcripts” were upregulated (“turned on”) by CBD and 524 were downregulated (“turned off”). The probe focused on CBD’s role in...

Read More